SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Board Changes

25 Sep 2025 07:00

RNS Number : 6929A
Porvair PLC
25 September 2025
 

 

For immediate release 25 September 2025

 

 

Porvair plc

("Porvair" or the "Group" or the "Company")

 

Board Changes

Lisa Anson

Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmBH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of the Listing Rules of the UK Listing Authority.

Sally Martin

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025.

Sheena Mackay

Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee.

For further information, please contact:

Porvair plc

+44 (0)1553 765 500

Hooman Caman Javvi, Chief Executive Officer

Andrew Douglass, Group Company Secretary

 

Burson Buchanan

+44 (0)207 466 5000

Charles Ryland / Stephanie Whitmore

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration, laboratory and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEZLFLEKLZBBF
Date   Source Headline
5th Dec 20197:00 amRNSPre-close trading update
2nd Dec 201911:20 amRNSHolding(s) in Company
2nd Dec 201911:20 amRNSHolding(s) in Company
13th Nov 20192:51 pmRNSHolding(s) in Company
31st Oct 20197:00 amRNSTotal Voting Rights
8th Oct 201910:00 amRNSBlock listing update
20th Sep 201911:38 amRNSDirector/PDMR Shareholding
18th Sep 20197:00 amRNSNine months trading update
5th Sep 20197:00 amRNSAcquisition of Dahlman Industrial Group B.V.
28th Aug 201912:07 pmRNSSecond Price Monitoring Extn
28th Aug 201912:02 pmRNSPrice Monitoring Extension
23rd Aug 201912:07 pmRNSSecond Price Monitoring Extn
23rd Aug 201912:02 pmRNSPrice Monitoring Extension
6th Aug 201912:07 pmRNSSecond Price Monitoring Extn
6th Aug 201912:02 pmRNSPrice Monitoring Extension
28th Jun 201911:30 amRNSDirector/PDMR Shareholding
27th Jun 20194:35 pmRNSPrice Monitoring Extension
24th Jun 20197:00 amRNSHalf Year Results 2019
18th Jun 20197:00 amRNSBoard changes
6th Jun 20197:00 amRNSTrading Update
15th Apr 201912:30 pmRNSHolding(s) in Company
11th Apr 20193:13 pmRNSAGM resolutions
11th Apr 20197:00 amRNSAGM Trading Update
26th Mar 20194:35 pmRNSPrice Monitoring Extension
22nd Mar 201910:59 amRNSHolding(s) in Company
8th Mar 20191:33 pmRNSHolding(s) in Company
12th Feb 201912:02 pmRNSDirector/PDMR Shareholding
28th Jan 20197:00 amRNSResults for the year ended 30 November 2018
24th Dec 201812:40 pmRNSSecond Price Monitoring Extn
24th Dec 201812:35 pmRNSPrice Monitoring Extension
7th Dec 20187:00 amRNSPre-close trading update
21st Sep 20189:57 amRNSDirector/PDMR Shareholding
18th Sep 20187:00 amRNSNine months trading update
7th Sep 20184:40 pmRNSSecond Price Monitoring Extn
7th Sep 20184:35 pmRNSPrice Monitoring Extension
29th Aug 20185:06 pmRNSDirector Declaration
10th Aug 20183:00 pmRNSDirector's Shareholding
10th Jul 20183:22 pmRNSHolding(s) in Company
25th Jun 20187:00 amRNSHalf Yearly Results
6th Jun 20187:00 amRNSTrading Update
1st May 20189:50 amRNSHolding(s) in Company
18th Apr 20184:40 pmRNSSecond Price Monitoring Extn
18th Apr 20184:35 pmRNSPrice Monitoring Extension
17th Apr 20182:21 pmRNSAGM resolutions and Board changes
17th Apr 20187:00 amRNSAGM Trading Update
6th Apr 20184:40 pmRNSSecond Price Monitoring Extn
6th Apr 20184:35 pmRNSPrice Monitoring Extension
19th Mar 20186:16 pmRNSDirector's Shareholding
1st Mar 20187:00 amRNSAcquisition of Keystone Filter
14th Feb 201812:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.